These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 14039067)

  • 41. The relationship between paroxetine and the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF; Hallas J; Skjelbo E; Allen A; Allen GD; Cooper SM; Mellows G; Tasker TC
    Clin Pharmacol Ther; 1992 Mar; 51(3):278-87. PubMed ID: 1531950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sparteine oxidation is practically abolished in quinidine-treated patients.
    Brinn R; Brøsen K; Gram LF; Haghfelt T; Otton SV
    Br J Clin Pharmacol; 1986 Aug; 22(2):194-7. PubMed ID: 3756067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New evidence of sparteine metabolites in humans.
    Pospísil J; Patzelová V; Máca B
    Drug Metab Dispos; 1992; 20(2):330-2. PubMed ID: 1352230
    [No Abstract]   [Full Text] [Related]  

  • 45. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.
    Brøsen K; Davidsen F; Gram LF
    Br J Clin Pharmacol; 1990 Feb; 29(2):248-53. PubMed ID: 2306418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.
    Sindrup SH; Brøsen K; Hansen MG; Aaes-Jørgensen T; Overø KF; Gram LF
    Ther Drug Monit; 1993 Feb; 15(1):11-7. PubMed ID: 8451774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Screening tests of microorganisms for the microbial transformation of griseophenone A, N-methylcoclaurine and sparteine].
    Isaka H; Minemura Y; Iida M; Okuda S; Iizuka H
    Eisei Shikenjo Hokoku; 1970; 88():144-9. PubMed ID: 6015286
    [No Abstract]   [Full Text] [Related]  

  • 48. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
    Holomán J; Glasa J; Veningerová M; Prachar V; Lukácsová M
    Bratisl Lek Listy; 1997 Feb; 98(2):86-90. PubMed ID: 9264814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proceedings: N-oxidation of sparteine in man and its interindividual differences.
    Eichelbaum M; Spannbrucker N; Dengler HJ
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R94. PubMed ID: 1143521
    [No Abstract]   [Full Text] [Related]  

  • 51. Studies on microbial transformation. XXVI. Microbial oxidation of (-)-sparteine.
    Furuya K; Aida K; Koiso Y; Okuda S
    Chem Pharm Bull (Tokyo); 1973 Jan; 21(1):231-4. PubMed ID: 4711516
    [No Abstract]   [Full Text] [Related]  

  • 52. Novel sparteine-mediated enantio-dichotomic formal synthesis of R-(-)- and S-(+)-curcuphenol.
    Kimachi T; Takemoto Y
    J Org Chem; 2001 Apr; 66(8):2700-4. PubMed ID: 11304190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thin-layer chromatographic screening test for polymorphic sparteine oxidation.
    Ebner T; Meese CO; Eichelbaum M
    Ther Drug Monit; 1989; 11(2):214-6. PubMed ID: 2718225
    [No Abstract]   [Full Text] [Related]  

  • 54. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.
    Sindrup SH; Brøsen K; Gram LF
    Clin Pharmacol Ther; 1992 Mar; 51(3):288-95. PubMed ID: 1531951
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glucuronidation clearance of 8-hydroxyclomipramine in relation to sparteine and mephenytoin phenotype.
    Nielsen KK; Brøsen K; Hansen MG; Gram LF
    Eur J Clin Pharmacol; 1994; 47(2):209-10. PubMed ID: 7859811
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of sparteine sulfate on insulin secretion in normal men.
    Sgambato S; Passariello N; Paolisso G; Bisesti V; Tesauro P
    Horm Metab Res; 1986 Oct; 18(10):686-8. PubMed ID: 3536704
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW; Moody DE
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.
    Klotz U; Mikus G; Zekorn C; Eichelbaum M
    Br J Clin Pharmacol; 1986 Nov; 22(5):618-20. PubMed ID: 3790411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.